TY - JOUR
T1 - Myasthenia gravis during pregnancy
AU - Ferrero, Simone
AU - Esposito, Francesca
AU - Biamonti, Mariangela
AU - Bentivoglio, Giorgio
AU - Ragni, Nicola
PY - 2008/6
Y1 - 2008/6
N2 - Myasthenia gravis (MG) affects women in the second and third decades of life, overlapping with the childbearing years. During pregnancy, the course of this disease is unpredictable; worsening of symptoms occurs more likely during the first half of pregnancy and postpartum. MG can be well managed during pregnancy with relatively safe and effective therapies. Cesarean section is recommended only for obstetric reasons; epidural anesthesia is advised to reduce physical and emotional stress. Anticholinesterase drugs are the mainstay of treatment, when MG symptoms are not satisfactorily controlled, corticosteroids, azathioprine and in some cases cyclosporin A may be used. Life-threatening conditions (e.g., respiratory insufficiency) may occur during pregnancy; therefore, intensive check-ups by a gynecologist and a neurologist are necessary.
AB - Myasthenia gravis (MG) affects women in the second and third decades of life, overlapping with the childbearing years. During pregnancy, the course of this disease is unpredictable; worsening of symptoms occurs more likely during the first half of pregnancy and postpartum. MG can be well managed during pregnancy with relatively safe and effective therapies. Cesarean section is recommended only for obstetric reasons; epidural anesthesia is advised to reduce physical and emotional stress. Anticholinesterase drugs are the mainstay of treatment, when MG symptoms are not satisfactorily controlled, corticosteroids, azathioprine and in some cases cyclosporin A may be used. Life-threatening conditions (e.g., respiratory insufficiency) may occur during pregnancy; therefore, intensive check-ups by a gynecologist and a neurologist are necessary.
KW - Delivery
KW - Diagnosis
KW - Myasthenia gravis
KW - Pregnancy
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=45749093276&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=45749093276&partnerID=8YFLogxK
U2 - 10.1586/14737175.8.6.979
DO - 10.1586/14737175.8.6.979
M3 - Article
C2 - 18505362
AN - SCOPUS:45749093276
SN - 1473-7175
VL - 8
SP - 979
EP - 988
JO - Expert Review of Neurotherapeutics
JF - Expert Review of Neurotherapeutics
IS - 6
ER -